| abstract |
Treatment of disease states, disorders and conditions associated with KEAP1-Nrf2 interactions such as Crohn's disease, pharmaceutical compositions containing them, methods of making them, and inflammatory bowel disease including Crohn's disease and ulcerative colitis. Concerning how to use these, including methods. |